Travere is eyeing a collective $3 billion U.S. opportunity for Filspari thanks to a new rare kidney disease nod, plus the med’s initial 2023 approval in another rare kidney indication.

Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, the FDA’s approval letter for the oral treatment shows lingering reservations about multiple “unexpected serious” risks potentially related to the drug.

Protagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson’s “largest products ever,” CEO Joaquin Duato said on the company’s first-quarter earnings conference call.

The AI will be used to analyze complex datasets and shrink R&D timelines, Novo said. It’ll additionally use the tech to seek efficiencies across manufacturing and corporate functions.

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately communicate the indication, contraindications and risks.

GSK and Shionogi’s ViiV Healthcare is seeking to raise awareness around what the company sees as a forgotten element in HIV: younger people with the infection.